Metkephamid

Summary

Metkephamid is a synthetic analogue of the endogenous opioid peptide methionine enkephalin, classified as a delta‑opioid receptor agonist. It has been explored in research settings for acute analgesia, particularly after surgery or postpartum episiotomy. Clinical trials using single parenteral doses (70–140 mg) reported pain relief comparable to the conventional opioid pethidine, with the higher dose showing the greatest efficacy. The compound remains investigational and is not approved for routine clinical use.

Mechanism of Action

Metkephamid mimics enkephalins and binds with high affinity to the δ‑opioid receptor, while also displaying measurable activity at μ receptors. δ‑receptor activation couples to Gi proteins, lowering intracellular cAMP and reducing neuronal excitability, thereby dampening nociceptive transmission in the central and peripheral nervous systems. Evidence from tolerance studies indicates that its analgesia persists in morphine‑tolerant models and is not antagonised by the μ‑selective blocker naloxazone, supporting a primary δ‑mediated effect. Additional anticholinergic‑like signs suggest secondary interaction with cholinergic pathways.

What the Research Shows

Early double‑blind, randomised trials compared a single intramuscular dose of metkephamid acetate (70 mg) with pethidine (100 mg) and placebo in postoperative patients, showing analgesic efficacy not inferior to pethidine and greater than placebo, but with a higher incidence of unique side‑effects such as limb heaviness and nasal congestion. In postpartum episiotomy pain, 140 mg metkephamid provided superior and longer‑lasting analgesia than 100 mg pethidine, while the 70 mg dose was indistinguishable from placebo. Cardiovascular studies in healthy volunteers (50 mg intramuscular) demonstrated increased heart rate without resting blood‑pressure change, but orthostatic hypotension after head‑up tilt, indicating delta‑mediated autonomic effects. Rat liver perfusion experiments revealed substantial first‑pass hepatic hydrolysis, with only 30–35 % of absorbed peptide reaching systemic circulation, a process mitigated by albumin binding. Pre‑clinical tolerance work showed that metkephamid’s analgesia is not cross‑tolerant with morphine, reinforcing its δ‑receptor contribution.

Reported Benefits

Clinical data indicate that metkephamid can provide analgesia comparable to pethidine, especially at a 140 mg dose, with a prolonged duration of effect (up to six hours) after a single injection. Its activity appears to be retained in morphine‑tolerant subjects, suggesting a potential advantage in patients with opioid tolerance. The peptide’s selective δ‑opioid activity may also confer a different side‑effect profile from μ‑agonists, avoiding typical μ‑related nausea and respiratory depression in the reported studies.

Limitations of the Evidence

Evidence is limited to small, short‑term clinical trials involving single doses; larger, multi‑dose studies are lacking. The lower 70 mg dose failed to outperform placebo, indicating a narrow therapeutic window. Oral administration is ineffective due to extensive first‑pass hepatic metabolism, restricting delivery routes to parenteral injection. Cardiovascular findings reveal orthostatic hypotension and anticholinergic‑like symptoms, which may limit use in susceptible populations. No data exist on long‑term safety, chronic dosing, or efficacy in diverse pain conditions.

Safety Considerations

Reported adverse effects include sensations of heavy limbs, nasal congestion, dry mouth, eye redness, and mild anticholinergic symptoms such as increased heart rate. In healthy volunteers, metkephamid caused orthostatic hypotension during head‑up tilt without raising plasma noradrenaline, suggesting impaired baroreflex responsiveness. While no severe respiratory depression was noted, the unique side‑effect profile warrants caution in patients with cardiovascular instability, glaucoma, or urinary retention. As the compound is investigational, comprehensive safety data are unavailable.

How It Is Administered

Metkephamid has been administered parenterally via intramuscular, intravenous, and subcutaneous routes, most commonly as the acetate salt in single‑dose injections. Formulations used in studies were aqueous solutions suitable for injection. Oral delivery is ineffective because of extensive hepatic first‑pass metabolism.

Routes of Administration

Goals & Uses

• Reduced respiratory depression vs. mu-opioidsSafety Profile InvestigationLow
• Opioid receptor subtype researchPharmacological ResearchHigh
• AnalgesiaPain ManagementModerate

Contraindications

• Known hypersensitivity to enkephalin analogsAllergyHigh
• Concurrent CNS depressant useDrug InteractionModerate

Adverse Effects

• DysphoriaPsychiatricUncommon
• HypotensionCardiovascularUncommonLow blood pressure
• Nausea and vomitingGastrointestinalCommon
• Respiratory depressionRespiratoryUncommon
• SedationCNSCommon

Drug Interactions

• Other opioid analgesicsModerate
• BenzodiazepinesHigh
• NaloxoneLow

Population Constraints

• Pediatric patientsAgeRelative
• Patients with hepatic impairmentOrgan FunctionRelative
• Patients with respiratory insufficiencyPulmonaryRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionUnapprovedNo marketing authorization sought or granted in European jurisdictions.
• United StatesUnapprovedInvestigated in clinical trials by Eli Lilly in the 1980s; never submitted for or received FDA approval.
• United KingdomUnapprovedNo regulatory approval; remains a research compound only.

Never received regulatory approval in any major jurisdiction. Investigated in Phase I/II clinical trials primarily in the 1980s. Remains a research compound.

Evidence & Sources

• Analgesic efficacy of parenteral metkephamid acetate in treatment of postoperative pain
  Journal ArticleModerateCalimlim JF, et al.1982-01-01T00:00:00.000000Z
• First-pass metabolism of peptide drugs in rat perfused liver
  Journal ArticleLowTaki Y, et al.1998-01-01T00:00:00.000000Z
• Metkephamid and meperidine analgesia after episiotomy
  Journal ArticleModerateBloomfield SS, Barden TP, Mitchell J1983-01-01T00:00:00.000000Z
• Central nervous system effects of peptides, 1980-1985: a cross-listing of peptides and their central actions from the first six years of the journal Peptides
  Journal ArticleModerateZadina JE, Banks WA, Kastin AJ1986-01-01T00:00:00.000000Z
• Cardiovascular properties of metkephamid, a delta opioid receptor agonist, in man
  Journal ArticleModeratePasanisi F, Sloan L, Rubin PC1985-01-01T00:00:00.000000Z
• Cross-tolerance studies distinguish morphine- and metkephamid-induced analgesia
  Journal ArticleLowHynes MD, Frederickson RC1982-01-01T00:00:00.000000Z

Frequently Asked Questions